New Patents Issued Across Multiple Geographies in US, Japan and Canada

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2016) BioAegis Therapeutics announces that
during 2016 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infectious disease, neurological disease and renal failure. The plasma gelsolin portfolio now includes more than 20 issued patents and many pending applications.


BioAegis Therapeutics announced that it has completed two successful manufacturing runs to produce lyophilized clinical supplies of plasma gelsolin. The drug product in this formulation has already been found to be highly temperature-stable in over two years of stability studies, which are ongoing. The lypophilization of biologics is utilized to eliminate the necessity of cold-chain storage, facilitating use in the clinic and minimizing storage and shipping costs.


National Institute of Allergy and Infectious Diseases awarded a 3-year $ 2.8 million grant to a partnership between BioAegis and TH Chan Harvard School of Public Health researchers. The grant will advance the study of pGSN replacement as a therapy for antibiotic-resistant pneumonia. The highly competitive R01 grant was responsive to a Request for Applications entitled: “Partnerships for the Development of Host-Targeted Therapeutics to Limit Antimicrobial Resistance.”

Read the full release NIH Grant Press Release June 9 2016


BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has sold a combination of net operating losses and R&D Credits totaling $544,000. The company’s application to this State of New Jersey’s Technology Business Tax Credit Transfer Program was previously accepted in June.


Company Develops Temperature-Stable Lyophilized Protein

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has successfully completed development of a lyophilized form of plasma gelsolin.
Lyophilization is the process of converting the bulk drug substance into a freeze-dried
form that can be stored in vials at room temperature. This eliminates the necessity of cold-chain storage, facilitating use in the clinic and minimizing storage and shipping costs.